Bid Banana
PricingBid helpAPILog inStart free trial
Log inStart free trial

Before you respond

  • Federal grantsHow to Find Grants for Nonprofits
  • Healthcare RFPsHealthcare and Medical Services Bids and Bidding Guide
  • How to apply for a grantGrant Applications vs. RFPs: Writing Differences Explained
More healthcare and medical services bids →Must-win bid? Bring in The Bid Lab →
Bid Banana
SearchPricingBid helpBrowse bidsAPISupportFAQPrivacy PolicyTerms of UseAI Use Policy

This website and its content is copyright of The Bid Lab © 2026. The Bid Lab is a trademark of Bid Lab, LLC. All rights reserved.

  1. Bid Banana
  2. ›Bids
  3. ›Federal
  4. ›Mechanisms that Impact Cancer Risk after Bariatric Surgery…

U.S. National Institutes of Health·United States of America

Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)

Closes 1/7/2028$200k – $275kGrants Notice
Get bids like this by emailBid source

Description

The National Cancer Institute invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk. The goal of this funding opportunity is to support proof of concept studies for feasibility and exploratory development. Key information about the job includes: * Investigator-initiated studies on the mechanisms of bariatric surgery's impact on cancer risk * Proof of concept studies for feasibility and exploratory development * The National Cancer Institute is the primary agency for this funding opportunity * The funding opportunity is for a period of 2 years for the R21 grant * Applications are due by January 7, 2028 * Eligible applicants include public and state-controlled institutions of higher education, non-profits, and small businesses, among others * The funding instrument for this opportunity is a grant * The funding activity categories include education and health * The expected application count is 100 * The expected application size is 0 Some key points to consider are: • Investigator-initiated studies are supported • Proof of concept studies are the primary focus • The National Cancer Institute is the primary agency • The funding opportunity is for a 2-year period • Eligible applicants include a variety of institutions and organizations • The funding instrument is a grant • The funding activity categories include education and health

Attached files

Contact

[email protected]

Key dates

Opened
9/5/2024
Closes
1/7/2028

Last updated

Details

Type
Grants Notice
Industry
Healthcare and Medical Services
NAICS
541710
Solicitation №
PAR-25-044

Budget estimate

$200,000 – $275,000

The budget for this grant is not explicitly stated in the document. However, based on the information provided, the total direct costs for the 2-year R21 grant are typically limited to $275,000, with no more than $200,000 in direct costs allowed in any single year. Therefore, the estimated budget range could be between $200,000 and $275,000. The factors influencing this estimate include the type of grant, the funding agency, and the typical funding amounts for similar grants.

AI estimate from the solicitation

Similar opportunities

Matched by Bid Banana AI™

Bid Banana · 1.6M+ bids and awards 🍌

You found this one. Bid Banana has 1.6M+ bids and awards.

You found this bid by looking. Bid Banana searches open government bids across all 50 states, updated daily, so you stop hunting: save a search once and we email you your new matches, daily or weekly.

1.6M+
bids & awards
All 50
states
4,000+
agencies
Start your 7-day free trial

Plans from $49.99/month. Cancel anytime, no setup fees.

Built by The Bid Lab, answering RFPs since 2017.

U.S. National Institutes of Health·United States of America

Top match · 97%

Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)

Closes 1/7/2028Opened 9/5/2024

U.S. National Institutes of Health·United States of America

83% match

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)

Closes 1/7/2027Opened 8/24/2023

U.S. National Institutes of Health·United States of America

82% match

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)

Closes 1/7/2027Opened 8/23/2023

U.S. National Institutes of Health·United States of America

82% match

Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)

Closes 9/7/2028Opened 11/12/2024

U.S. National Institutes of Health·United States of America

81% match

Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)

Closes 11/6/2026Opened 8/1/2023

U.S. National Institutes of Health·United States of America

81% match

Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)

Closes 11/17/2026Opened 8/1/2023

U.S. National Institutes of Health·United States of America

81% match

Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional)

Closes 10/11/2029Opened 3/10/2026

U.S. National Institutes of Health·United States of America

81% match

Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)

Closes 1/7/2027Opened 12/15/2023

U.S. National Institutes of Health·United States of America

80% match

National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)

Closes 1/7/2027Opened 12/15/2023

U.S. National Institutes of Health·United States of America

80% match

Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)

Closes 10/25/2027Opened 6/23/2022

U.S. National Institutes of Health·United States of America

80% match

Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)

Closes 11/16/2027Opened 11/18/2024

U.S. National Institutes of Health·United States of America

80% match

Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)

Closes 7/5/2029Opened 6/16/2025

U.S. National Institutes of Health·United States of America

79% match

Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Closes 11/10/2026Opened 9/8/2025

U.S. National Institutes of Health·United States of America

79% match

Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)

Closes 2/11/2028Opened 11/7/2024

U.S. National Institutes of Health·United States of America

79% match

Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

Closes 11/10/2026Opened 9/8/2025

U.S. National Institutes of Health·United States of America

78% match

Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)

Closes 1/7/2028Opened 11/18/2024

U.S. National Institutes of Health·United States of America

78% match

Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)

Closes 1/7/2027Opened 9/21/2023

U.S. National Institutes of Health·United States of America

78% match

Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

Closes 1/7/2028Opened 11/6/2024

U.S. National Institutes of Health·United States of America

78% match

Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)

Closes 7/20/2028Opened 6/9/2025

U.S. National Institutes of Health·United States of America

78% match

Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed)

Closes 1/7/2027Opened 9/29/2023

U.S. National Institutes of Health·United States of America

78% match

Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

Closes 6/3/2027Opened 7/14/2026

U.S. National Institutes of Health·United States of America

78% match

Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Closes 6/3/2027Opened 7/14/2026

U.S. National Institutes of Health·United States of America

78% match

Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)

Closes 10/25/2027Opened 6/23/2022

U.S. National Institutes of Health·United States of America

77% match

Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)

Closes 1/7/2028Opened 1/11/2022

U.S. National Institutes of Health·United States of America

77% match

Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)

Closes 11/2/2026Opened 11/6/2023